G
Gene D. Morse
Researcher at University at Buffalo
Publications - 243
Citations - 6205
Gene D. Morse is an academic researcher from University at Buffalo. The author has contributed to research in topics: Efavirenz & Ritonavir. The author has an hindex of 39, co-authored 236 publications receiving 5837 citations. Previous affiliations of Gene D. Morse include AIDS Clinical Trials Group & National Institutes of Health.
Papers
More filters
Journal ArticleDOI
Once-a-Day Concerta Methylphenidate Versus Three-Times-Daily Methylphenidate in Laboratory and Natural Settings
William E. Pelham,Elizabeth M. Gnagy,Lisa Burrows-MacLean,Andrew Williams,Gregory A. Fabiano,Sean M. Morrisey,Andrea M. Chronis,Gregory L. Forehand,Celeste A. Nguyen,Martin T. Hoffman,Thomas M. Lock,Karl Fielbelkorn,Erika K. Coles,Carlos J. Panahon,Randi L. Steiner,David L. Meichenbaum,Adia N. Onyango,Gene D. Morse +17 more
TL;DR: This study tests the efficacy and duration of action, in natural and laboratory settings, of an extended-release MPH preparation designed to last 12 hours and therefore be equivalent to 3-times-daily dosing of MPH and results support the use of background behavioral treatment in clinical trials of stimulant medication.
Journal ArticleDOI
2′,3′-Dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex: a phase I trial.
John S. Lambert,Mindell Seidlin,Richard C. Reichman,C S Plank,M Laverty,Gene D. Morse,C Knupp,Christine E. McLaren,Carla Pettinelli,Fred T. Valentine +9 more
TL;DR: It is concluded that ddI is a promising therapeutic agent in patients with AIDS or AIDS-related complex and its efficacy is currently being evaluated in large-scale, controlled clinical trials.
Journal ArticleDOI
Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: an Adult Aids Clinical Trials Group Study
David W. Haas,Laura M. Smeaton,Robert W. Shafer,Gregory K. Robbins,Gene D. Morse,Line Labbé,Grant R. Wilkinson,David B. Clifford,Richard T. D'Aquila,Victor De Gruttola,Richard B. Pollard,Thomas C. Merigan,Martin S. Hirsch,Alfred L. George,John P. Donahue,Richard B. Kim +15 more
TL;DR: Genetic variants predict plasma exposure to efavirenz and nelfinavir, and they may predict virologic failure and/or emergence of drug-resistant virus.
Journal ArticleDOI
Comparison of Four-Drug Regimens and Pairs of Sequential Three-Drug Regimens as Initial Therapy for HIV-1 Infection
Robert W. Shafer,Laura M. Smeaton,Gregory K. Robbins,Victor De Gruttola,Sally Snyder,Richard T. D'Aquila,Victoria A. Johnson,Gene D. Morse,Mostafa Nokta,Ana Martinez,Barbara Gripshover,Pamposh Kaul,Richard Haubrich,Mary Swingle,S. Debra McCarty,Stefano Vella,Martin S. Hirsch,Thomas C. Merigan +17 more
TL;DR: There was no significant difference in the duration of successful HIV-1 treatment between a single four-drug regimen and two consecutive three-drug regimens and among these treatment strategies, initiating therapy with the three- drug regimen of zidovudine, lamivudine and efavirenz is the optimal choice.
Journal ArticleDOI
Clinical Pharmacokinetics of Non-Nucleoside Reverse Transcriptase Inhibitors
TL;DR: Non-nucleoside reverse transcriptase inhibitors are a diverse group of compounds that induce allosteric changes in the human immunodeficiency virus type 1 (HIV-1)reverse transcriptase, thus rendering the enzyme incapable of converting viral RNA to DNA.